High adherence to the Mediterranean diet is associated with a reduced risk for SLE, with the relationship partially mediated by certain liver and kidney function biomarkers.

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected ...

RemeGen announced that it plans to submit a Biologics License Application (BLA) to the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China for primary ...

In a comprehensive study, researchers from the Department of Epidemiology at the Faculty of Medicine at the University of ...

Yantai-based RemeGen said it will now move ahead with filing telitacicept with China's National Medical Products Administration (NMPA), which has already approved the drug as a treatment for ...

Zenas BioPharma, Inc. ( ($ZBIO) ) has released its Q2 earnings. Here is a breakdown of the information Zenas BioPharma, Inc. presented to its ...

Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Adicet Bio (NASDAQ:ACET), a biotechnology company focused on gamma delta T cell therapies for autoimmune diseases and cancer, reported its second quarter 2025 earnings on August 7 ...

Net loss was $23.0 million, or $0.31 per basic and diluted share, for the second quarter of 2025. This net loss includes non-cash charges of $3.4 million that consisted primarily of share-based ...